14.44
-0.23 (-1.57%)
Penutupan Terdahulu | 14.67 |
Buka | 14.67 |
Jumlah Dagangan | 594,046 |
Purata Dagangan (3B) | 1,001,491 |
Modal Pasaran | 1,176,643,328 |
Harga / Jualan (P/S) | 3.25 |
Harga / Buku (P/B) | 2.44 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
Margin Operasi (TTM) | -121,488.89% |
EPS Cair (TTM) | -3.07 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 3.44% |
Nisbah Semasa (MRQ) | 15.43 |
Aliran Tunai Operasi (OCF TTM) | -232.32 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -136.82 M |
Pulangan Atas Aset (ROA TTM) | -30.32% |
Pulangan Atas Ekuiti (ROE TTM) | -48.48% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Viridian Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -2.5 |
Purata | 1.00 |
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 0.12% |
% Dimiliki oleh Institusi | 114.06% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
07 Apr 2025 | Pengumuman | Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors |
10 Mar 2025 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
27 Feb 2025 | Pengumuman | Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results |
06 Feb 2025 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |